Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV-CORE 004: HIV-1 Vaccines in Healthy Adults
NCT02099994Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2014
- Primary completion
- Aug 2015
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of Oxford. Primary endpoint: Vaccine Safety at 44 weeks. Started Mar 2014; status: completed.
02
Drugs
pSG2.HIVconsv DNAMVA.HIVconsvAd35-GRIN
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02099994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099994.